# PRAXIS SIMULATION SUITE
## Enterprise-Grade Strategy Simulation Design Specification

Version 1.0 | Classification: Product Design Input | Status: Authoritative

---

# GAME 1: NEXUS PROTOCOL
## Platform Launch Under Regulatory Uncertainty

---

### A. CORE SCENARIO

**Industry Context**

Nexus Protocol places participants inside a technology company attempting to launch a two-sided digital platform in the healthcare data exchange space. The company, MedLink Technologies, has developed proprietary middleware that enables seamless data sharing between hospital systems, insurance providers, pharmaceutical researchers, and patients. The platform operates at the intersection of healthcare IT, data privacy regulation, and emerging AI diagnostics.

The healthcare data exchange market is nascent but growing at 34% annually. Three major incumbent players control legacy integration systems but have failed to create true interoperability. MedLink's technology genuinely solves problems that have plagued the industry for two decades. However, the regulatory environment is fragmenting rather than consolidating. HIPAA compliance is table stakes, but new state-level privacy laws, EU adequacy decisions affecting international data flows, and pending FDA guidance on AI-derived diagnostics create a compliance matrix that shifts quarterly.

**Company Maturity**

MedLink Technologies is a Series C company with $127 million in total funding. The company has 340 employees, with engineering representing 58% of headcount. The platform has been in limited beta with 12 hospital systems and 3 regional insurance providers for 18 months. Technical validation is strong. Commercial validation remains unproven at scale.

The company burns $4.2 million monthly. Current runway extends 16 months without additional revenue or funding. The board includes two venture partners who led previous rounds, one independent director with healthcare operations background, and the CEO who holds a board seat. A Series D conversation is possible in 12 months if commercial metrics justify valuation expectations.

**Competitive Landscape**

Three categories of competitors threaten MedLink's market entry:

Legacy integration vendors (Epic, Cerner, Meditech) possess deep hospital relationships and switching cost advantages. They have announced interoperability initiatives but execution has been slow. Their platforms are closed gardens that benefit from data lock-in. They view MedLink as an existential threat to their business model.

Cloud hyperscalers (Google Health, Microsoft Cloud for Healthcare, Amazon HealthLake) bring massive infrastructure advantages and brand trust with enterprise buyers. However, healthcare-specific expertise remains thin. Their go-to-market relies on existing enterprise relationships rather than healthcare-native sales motions. Privacy concerns from consumer data practices create friction with hospital compliance officers.

Emerging point solutions (Health Gorilla, Particle Health, Redox) compete directly in the interoperability middleware space. They are smaller than MedLink but have established revenue bases. Several have achieved HITRUST certification ahead of MedLink. Partnership or acquisition conversations are possible but complicated by competitive dynamics.

**Macro and Regulatory Environment**

The federal regulatory posture is shifting from prescriptive to outcome-based. CMS has signaled intent to mandate data sharing capabilities for Medicare reimbursement eligibility within 36 months, but rulemaking timelines are uncertain. State attorneys general have become aggressive on health data privacy enforcement following several high-profile breaches at other companies.

The European market represents expansion opportunity but GDPR compliance costs are substantial. UK market access post-Brexit requires separate regulatory engagement. Asian markets are fragmented with country-specific data localization requirements.

Political risk is elevated. Healthcare data has become a partisan issue. Congressional hearings on tech companies and health data are scheduled. MedLink has not been named directly but operates in the zone of scrutiny. A single negative news cycle could trigger regulatory attention.

**Initial Strategic Tension**

MedLink must decide whether to pursue aggressive market expansion to establish network effects before competitors respond, or adopt a conservative posture that prioritizes regulatory certainty before scaling. Neither path is obviously correct.

Aggressive expansion risks regulatory backlash if compliance gaps emerge at scale. The company may win market share but face enforcement actions that destroy enterprise value. Conservative waiting risks losing the market window as competitors improve their offerings or hyperscalers acquire point solutions.

The board is divided. Venture investors favor speed. The independent director counsels caution. The CEO must navigate this tension while managing a leadership team with divergent views on risk tolerance.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: First-Mover Advantage**

Market structure favors early movers. Two major hospital systems have issued RFPs with decision timelines of 90 days. Winning both would establish MedLink as category leader. However, the compliance team has flagged gaps in the company's HITRUST certification process. Full certification is 6 months away. Competitors with certification are bidding.

Cost base is lean. Engineering efficiency is high. Sales team is understaffed relative to pipeline opportunity. Marketing has generated demand that exceeds capacity to respond.

Talent profile skews technical. Product management is strong. Commercial leadership is developing. The VP of Sales joined 8 months ago from a successful exit but has not yet built a high-performing team.

Regulatory pressure is moderate but rising. No enforcement actions pending. Industry association relationships are positive. However, a competitor recently received a warning letter that signals increased agency attention to the space.

Brand trust is high among technical buyers, moderate among compliance officers, and low among C-suite hospital executives who have not heard of the company.

Financial runway is 16 months. Series D interest is strong contingent on commercial proof points.

**Configuration 2: Regulatory Headwinds**

Market structure is contested. Hospital systems are delaying purchasing decisions pending regulatory clarity. A recent enforcement action against an adjacent company has created risk aversion among procurement teams. Sales cycles have extended from 6 months to 12 months.

Cost base is elevated. The company hired aggressively in anticipation of growth that has not materialized. Monthly burn has increased to $5.1 million. Runway is 13 months without cuts.

Talent profile includes strong regulatory expertise. The General Counsel previously served at HHS and maintains agency relationships. This expertise comes at premium compensation cost.

Regulatory pressure is high. The company has received an informal inquiry from a state attorney general. The inquiry is routine but consumes management attention and legal resources. Resolution timeline is uncertain.

Brand trust has been damaged by industry-wide scrutiny. MedLink has not been accused of wrongdoing but suffers from category association.

Financial runway is constrained. Series D conversations have paused pending regulatory clarity. Bridge financing is available but dilutive.

**Configuration 3: Partnership Dependent**

Market structure favors ecosystem players. The largest hospital system in the target market has indicated willingness to partner with MedLink on a joint development agreement that would provide revenue, validation, and market access. However, the partnership terms require exclusivity provisions that would limit MedLink's ability to serve competing hospital systems for 24 months.

Cost base is moderate. The company has maintained discipline but has not invested in sales infrastructure, relying instead on partnership-driven distribution.

Talent profile lacks commercial depth. Engineering and product are strong. Sales and marketing are skeletal. The company cannot pursue direct enterprise sales without significant hiring.

Regulatory pressure is low. The partnership would provide regulatory cover through the hospital system's existing compliance infrastructure.

Brand trust is concentrated. The company is well-known to the potential partner but invisible to the broader market.

Financial runway is 18 months. The partnership would extend runway through revenue and potentially through strategic investment from the hospital system's venture arm.

**Configuration 4: International Expansion**

Market structure in the domestic market is saturated with competitors. Growth requires international expansion. The UK NHS has issued a tender for interoperability solutions as part of digital transformation initiatives. Winning the NHS contract would establish MedLink as a global player.

Cost base is optimized for domestic operations. International expansion requires significant investment in local compliance, sales, and support infrastructure.

Talent profile is domestic-focused. No employees have international healthcare regulatory experience. Key hires would be required.

Regulatory pressure domestically is moderate. International expansion introduces GDPR, UK data protection, and NHS-specific requirements that the company has not yet addressed.

Brand trust is strong domestically but nonexistent internationally.

Financial runway is 16 months. International expansion would accelerate burn significantly. Success would unlock access to EU and UK capital markets. Failure would consume runway without domestic progress.

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

**STRATEGY ROLE**

Unique Private Information: Strategy sees board dynamics that other roles do not. They know that one venture investor is facing fund lifecycle pressure and needs liquidity within 24 months. They know that the independent director has been approached about joining a competitor's board. They see preliminary M&A interest from a hyperscaler that has not been shared with the full leadership team.

Decision Levers Available Per Round:
- Resource allocation across business units (percentage splits, minimum 10% increments)
- Strategic initiative prioritization (maximum 3 active initiatives per round)
- Board communication strategy (transparency level, narrative framing)
- M&A engagement posture (ignore, explore, negotiate, accept)
- Competitive response authorization (budget and messaging boundaries for other functions)

Time-Delayed Consequences: Strategic pivots take 2-3 rounds to manifest in operational metrics. Board confidence changes lag strategic decisions by 1 round as directors observe execution. M&A conversations initiated in one round do not reach term sheet stage until round 3-4.

Conflicts With Other Roles: Strategy conflicts with Sales over growth targets that may be unrealistic given regulatory constraints. Strategy conflicts with Legal over risk tolerance in new market entry. Strategy often wants to move faster than Legal advises and slower than Sales demands.

Internal vs External Metrics: Internally, Strategy is judged on board confidence, strategic clarity, and competitive positioning. Externally, Strategy is judged on valuation trajectory and market share. These metrics can diverge significantly in the short term.

**MARKETING ROLE**

Unique Private Information: Marketing sees customer perception data that other roles do not. They know that hospital CIOs privately express interest but compliance officers are blocking procurement. They know that a major industry analyst is preparing a report that will either validate or criticize MedLink's approach. They have intelligence on competitor messaging strategies from channel partners.

Decision Levers Available Per Round:
- Brand positioning (technical excellence vs. compliance leadership vs. innovation pioneer)
- Channel mix allocation (direct marketing, industry events, analyst relations, content marketing)
- Message development and approval (claims that can be made, evidence requirements)
- Demand generation targets (volume vs. quality tradeoffs)
- Crisis communication preparation (pre-positioned statements, media relationships)

Time-Delayed Consequences: Brand investments take 3-4 rounds to influence enterprise buyer perception. Analyst relations work begun in round 1 produces coverage in round 3-4. Demand generation shows pipeline impact in round 2-3 but closed revenue in round 5-6.

Conflicts With Other Roles: Marketing conflicts with Sales over lead quality and handoff processes. Marketing conflicts with Legal over claims that can be made in market-facing materials. Marketing wants to make bold claims; Legal wants to minimize litigation risk.

Internal vs External Metrics: Internally, Marketing is judged on pipeline contribution and brand awareness. Externally, Marketing is judged on market positioning and share of voice. Pipeline that does not convert damages internal standing even if brand metrics improve.

**PRODUCT / SUPPLY ROLE**

Unique Private Information: Product sees technical debt and platform stability data that other roles do not. They know that a critical integration is held together with workarounds that will not scale. They know that a key engineer is considering departure. They have early signal on emerging technology standards that could obsolete current architecture.

Decision Levers Available Per Round:
- Roadmap prioritization (customer requests vs. technical debt vs. new capabilities)
- Platform investment allocation (stability, scalability, new features)
- Build vs. buy decisions for capability gaps
- Technical partnership terms (API access, data sharing, integration depth)
- Release timing and scope (feature completeness vs. speed to market)

Time-Delayed Consequences: Technical debt deferred in early rounds compounds and constrains options in later rounds. Platform investments made in rounds 1-3 determine scalability constraints in rounds 6-10. Partnership integrations begun early enable or foreclose strategic options later.

Conflicts With Other Roles: Product conflicts with Sales over feature commitments made to close deals. Product conflicts with R&D over resource allocation between maintenance and innovation. Product wants to build sustainable systems; Sales wants to win deals now.

Internal vs External Metrics: Internally, Product is judged on platform reliability, roadmap execution, and technical team retention. Externally, Product is judged on feature competitiveness and time-to-market. A stable platform with missing features may score well internally but poorly externally.

**R&D ROLE**

Unique Private Information: R&D sees emerging technology intelligence that other roles do not. They know that a university research group has published work that could leapfrog MedLink's core technology within 18 months. They know that a patent application is likely to be challenged. They have visibility into competitor technical hiring that signals strategic direction.

Decision Levers Available Per Round:
- Research investment allocation (near-term improvement vs. next-generation platform)
- Patent strategy (defensive filing, offensive assertion, licensing posture)
- Academic and research partnerships (exclusive vs. non-exclusive, publication rights)
- Technical talent acquisition priorities
- Innovation pipeline management (kill, continue, accelerate decisions)

Time-Delayed Consequences: Research investments made in rounds 1-2 produce deployable technology in rounds 5-7. Patent filings in early rounds face examination in mid-game and potential challenges in late game. Talent acquisitions take 1 round to close and 2 rounds to become productive.

Conflicts With Other Roles: R&D conflicts with Product over resource allocation between research and development. R&D conflicts with Strategy over long-term bets that may not align with current market positioning. R&D wants to pursue technically elegant solutions; Product wants shippable features.

Internal vs External Metrics: Internally, R&D is judged on innovation pipeline, patent portfolio, and technical talent density. Externally, R&D is judged on product differentiation and technology leadership. A strong patent portfolio may not translate to market-recognized innovation.

**SALES ROLE**

Unique Private Information: Sales sees customer buying signals and competitive intelligence that other roles do not. They know that a key prospect is in final negotiations with a competitor and the specific objections being raised. They know that a current customer is considering expansion or churn. They have intelligence on competitor pricing from customers who have seen competing proposals.

Decision Levers Available Per Round:
- Territory and account prioritization
- Pricing authority and discounting boundaries
- Sales team structure and compensation design
- Partner channel development and management
- Customer success resource allocation (new vs. existing customers)

Time-Delayed Consequences: Pipeline developed in round N closes in round N+2 to N+4 depending on deal size. Pricing decisions in early rounds establish market expectations that constrain later flexibility. Customer success investments prevent churn that would otherwise manifest 3-4 rounds later.

Conflicts With Other Roles: Sales conflicts with Product over feature gaps that lose deals. Sales conflicts with Legal over contract terms that customers demand but Legal considers risky. Sales wants to close deals; Legal wants to manage liability.

Internal vs External Metrics: Internally, Sales is judged on quota attainment, pipeline coverage, and sales efficiency. Externally, Sales is judged on market share and customer logos. Hitting quota through heavy discounting may satisfy internal metrics while damaging external competitive position.

**LEGAL / REGULATORY ROLE**

Unique Private Information: Legal sees regulatory intelligence and litigation risk that other roles do not. They know that an enforcement action against a competitor has implications for MedLink that have not been publicly analyzed. They know that a contract term in a customer agreement creates liability exposure that Sales does not understand. They have relationships with regulators that provide informal guidance not available to competitors.

Decision Levers Available Per Round:
- Compliance investment prioritization (certifications, audits, training)
- Regulatory engagement strategy (proactive, reactive, adversarial)
- Contract template evolution (risk allocation, limitation of liability)
- Litigation posture (settle, fight, preempt)
- Policy advocacy participation (industry associations, direct lobbying)

Time-Delayed Consequences: Compliance investments made in rounds 1-3 determine audit outcomes in rounds 4-6. Regulatory relationships built early provide protection during enforcement cycles later. Contract terms accepted in early deals establish precedents that customers expect in later deals.

Conflicts With Other Roles: Legal conflicts with Sales over deal terms that accelerate close but create risk. Legal conflicts with Strategy over market entry timing when regulatory clarity is lacking. Legal wants to minimize risk; Strategy wants to capture opportunity.

Internal vs External Metrics: Internally, Legal is judged on compliance status, litigation outcomes, and regulatory relationships. Externally, Legal is judged on the company's reputation for trustworthiness and regulatory standing. Strong internal compliance may not translate to external trust if communication is poor.

**GENERAL MANAGEMENT ROLE**

Unique Private Information: General Management sees organizational dynamics that other roles do not. They know that two executives have unresolved conflict that is affecting cross-functional collaboration. They know that employee engagement scores have declined in specific teams. They see cash flow projections that create constraints not visible to functional leaders.

Decision Levers Available Per Round:
- Executive team composition and performance management
- Organizational structure and reporting relationships
- Capital allocation across functions
- Culture and values reinforcement mechanisms
- External stakeholder communication (investors, press, customers)

Time-Delayed Consequences: Organizational changes take 2-3 rounds to affect operational performance. Executive departures create 1-2 round capability gaps while replacements onboard. Culture investments show engagement impact in 2-3 rounds and performance impact in 4-5 rounds.

Conflicts With Other Roles: General Management must mediate conflicts between all other roles. They face pressure from Sales to prioritize revenue, from Legal to prioritize compliance, from R&D to prioritize innovation, and from Strategy to prioritize positioning. Every function believes their priorities should dominate.

Internal vs External Metrics: Internally, General Management is judged on organizational health, executive team effectiveness, and resource efficiency. Externally, General Management is judged on company performance and leadership reputation. Strong internal metrics may not produce external results if strategic direction is flawed.

---

### D. ROUND STRUCTURE AND PACING

**Round Duration and Cadence**

The simulation runs 8 rounds representing 2 years of company operations (quarterly cycles). Each round requires approximately 20-25 minutes of active play, with natural breakpoints for facilitator intervention and team discussion.

**Phase 1: Sensemaking (5 minutes)**

Each role receives a confidential briefing document containing:
- Role-specific metrics from the previous round
- Private intelligence relevant to their function
- Emerging signals that may indicate threats or opportunities
- Requests or demands from other roles that require response

Information revealed at this phase:
- Quantitative performance data (revenue, pipeline, compliance status, technical metrics)
- Qualitative intelligence (customer sentiment, competitive moves, regulatory signals)
- Internal organizational dynamics (team morale, cross-functional friction indicators)

Information that remains hidden:
- Other roles' private intelligence
- System-level dynamics that will manifest in future rounds
- Competitor strategic intentions (only observable actions are revealed)
- Regulatory decision timelines (agencies do not communicate clearly)

Misinformation and noise present:
- Customer signals may be misleading (prospects that seem committed may be using MedLink for leverage with competitors)
- Competitive intelligence may be outdated or planted
- Regulatory guidance may be informal and subject to reversal
- Market size estimates vary significantly across sources

**Phase 2: Decision Submission (8 minutes)**

Roles must submit decisions using structured decision forms. Each role has 3-5 mandatory decisions per round plus optional decisions that consume additional decision capacity.

Decision categories:
- Resource allocation (how to deploy budgeted resources)
- Strategic choices (which opportunities to pursue, which to decline)
- Relationship management (how to engage with stakeholders)
- Risk posture (how much uncertainty to accept)

Constraints on decision submission:
- Budget limits enforce trade-offs (cannot fund everything)
- Time limits prevent unlimited analysis (must decide with incomplete information)
- Coordination requirements create interdependencies (some decisions require alignment with other roles)
- Decision capacity limits prevent over-optimization (maximum 8 total decisions per role per round)

**Phase 3: System Resolution (Facilitator-driven, 5 minutes)**

The simulation engine processes all decisions and produces outcomes based on:
- Direct effects of individual decisions
- Interaction effects between decisions across roles
- Stochastic elements representing market and regulatory uncertainty
- Historical path dependency from previous rounds

Resolution reveals:
- Immediate outcomes of decisions made this round
- Lagged outcomes of decisions made in previous rounds
- Exogenous events triggered by probability systems
- Competitor responses to MedLink's market actions

Resolution conceals:
- Precise causal attribution (players cannot perfectly determine which decisions produced which outcomes)
- Future probability distributions (players know events are possible but not their likelihood)
- Competitor decision-making rationale (only actions are observable)

**Phase 4: Feedback and Narrative Update (7 minutes)**

Each role receives updated dashboards showing:
- Key performance indicators relevant to their function
- Trend lines indicating trajectory
- Warning indicators for metrics approaching critical thresholds
- Narrative text providing context for quantitative changes

Cross-functional visibility:
- All roles see company-level metrics (revenue, cash, headcount, market share)
- Roles see partial information about adjacent functions (Sales sees Product roadmap commitments, Legal sees deals pending contract review)
- No role sees complete information about all functions

Facilitator narration:
- Facilitator provides 2-3 minutes of narrative context describing the state of the company
- Narrative includes qualitative color that cannot be captured in metrics
- Facilitator may introduce additional information based on the specific trajectory of the simulation

---

### E. DECISION TREES AND BRANCHING PATHS

**Strategic Fork 1: Regulatory Engagement Posture (Round 2-3)**

Trigger: A state attorney general announces an investigation into health data practices in the industry. MedLink is not named but operates in the space under scrutiny.

Path A - Proactive Engagement: MedLink voluntarily contacts the AG's office, offers cooperation, and proposes to serve as an industry model for compliance. This path requires significant legal resource allocation and may reveal information that the company would prefer to keep confidential. However, it positions MedLink as a trusted actor and may result in favorable treatment if enforcement actions follow.

Consequences of Path A:
- Legal costs increase 40% for 2 rounds
- Sales cycles extend as customers await regulatory clarity
- Brand positioning as compliance leader becomes credible
- Regulatory relationships strengthen, providing future optionality
- Competitors who do not engage proactively may face harsher scrutiny later
- Information disclosed during cooperation may limit future product directions

Path B - Defensive Posture: MedLink maintains current compliance practices without proactive engagement. The company monitors the investigation but does not volunteer information or contact. This preserves resources and flexibility but risks being caught unprepared if enforcement expands.

Consequences of Path B:
- Legal costs remain baseline
- Sales cycles unaffected initially but vulnerable to future disruption
- Compliance positioning remains undifferentiated
- Regulatory relationships remain transactional
- If investigation expands to MedLink, company faces scrutiny without established goodwill
- Product flexibility preserved but regulatory risk accumulates

Path C - Industry Coalition: MedLink joins with competitors to form an industry association response. This distributes costs and creates collective bargaining power with regulators. However, it requires coordination with competitors and may constrain MedLink's ability to differentiate on compliance.

Consequences of Path C:
- Legal costs shared across industry (reduced 25%)
- Industry-standard compliance framework emerges that all players must meet
- MedLink cannot claim compliance leadership as differentiator
- Regulatory burden distributed but MedLink's specific practices may be forced to change to meet industry standard
- Creates ongoing relationship with competitors that may enable or constrain future strategy
- Delays resolution as coalition requires consensus decision-making

Lock-out effects: Choosing Path A forecloses Path C (cannot join coalition after demonstrating willingness to cooperate individually). Choosing Path C limits ability to pursue Path A later (coalition membership requires unified posture).

**Strategic Fork 2: Technology Platform Investment (Round 3-4)**

Trigger: Technical assessment reveals that current platform architecture will not scale beyond 500 enterprise customers without fundamental re-architecture. Current customer count is 45 with pipeline suggesting 200+ within 18 months.

Path A - Incremental Scaling: Invest in optimizing current architecture to extend scalability threshold. This path is faster and cheaper but creates technical debt that constrains future options. Platform can likely reach 300-400 customers before hitting hard limits.

Consequences of Path A:
- R&D costs remain baseline
- Time to improved scalability: 2 rounds
- Technical debt increases, creating maintenance burden
- Customer acquisition can continue without pause
- Future re-architecture still required but can be deferred
- Platform reliability risk increases as customer count grows
- Engineering team morale may decline as they implement workarounds rather than solutions

Path B - Full Re-architecture: Invest in fundamental platform rebuild that addresses scalability limits permanently. This path is expensive and creates a 3-4 round period where new feature development slows significantly.

Consequences of Path B:
- R&D costs increase 80% for 3 rounds
- Time to new platform: 4 rounds
- Technical debt eliminated
- Customer acquisition slows during transition (cannot onboard new customers as quickly)
- Competitive window may close while MedLink focuses internally
- Long-term platform advantages emerge in rounds 6-8
- Engineering team energized by greenfield development
- Risk of project failure or delay that leaves company with neither old nor new platform

Path C - Hybrid Architecture: Pursue parallel development of new platform while maintaining current system. This path is most expensive but preserves short-term competitiveness while building long-term capability.

Consequences of Path C:
- R&D costs increase 120% for 4 rounds
- Maintains current customer growth trajectory
- New platform available in 5 rounds
- Requires significant engineering hiring and management complexity
- Risk of organizational confusion as two platforms coexist
- Migration from old to new platform creates customer disruption in rounds 6-7
- Cash burn significantly accelerated, potentially requiring additional funding

Lock-out effects: Choosing Path A limits future ability to pursue Path B (technical debt compounds, making re-architecture progressively more expensive). Choosing Path B during rounds 3-4 may preclude capturing market share that competitors seize during development period.

**Strategic Fork 3: Market Expansion vs. Deepening (Round 5-6)**

Trigger: MedLink has established position in mid-market hospital segment. Two expansion opportunities emerge simultaneously: international expansion to UK NHS, and upmarket expansion to top-20 US health systems.

Path A - International Expansion: Pursue UK NHS opportunity. This requires establishing UK entity, hiring local team, achieving NHS certification, and adapting platform for UK healthcare data standards.

Consequences of Path A:
- Geographic diversification reduces US regulatory risk
- NHS contract provides significant revenue and reference value
- UK market access enables EU expansion pathway
- US market share growth pauses during international focus
- Currency risk and operational complexity introduced
- Management attention divided across geographies
- If NHS implementation fails, company reputation damaged in both markets

Path B - Upmarket Expansion: Pursue top-20 US health system opportunity. This requires enterprise sales capability, enhanced platform security and scalability, and executive relationships at target accounts.

Consequences of Path B:
- US market leadership position strengthened
- Enterprise customer revenue significantly higher than mid-market
- Reference customers enable broader mid-market acceleration
- Concentration risk if large customer churns
- Enterprise sales cycles are 12-18 months, delaying revenue impact
- Enterprise requirements may force product changes that complicate mid-market offering
- Direct competition with incumbent vendors at their strongest

Path C - Market Deepening: Focus on capturing remaining mid-market opportunity before expansion. This requires optimization of current sales and delivery motion.

Consequences of Path C:
- Operational efficiency improves
- Market share in mid-market segment grows substantially
- Competitors may capture upmarket and international positions that become entrenched
- Expansion opportunities may not be available later if windows close
- Lower risk execution but lower potential upside
- Investors may view as insufficiently ambitious, affecting Series D

Lock-out effects: International and upmarket expansion both require resources that preclude simultaneous pursuit. Choosing Path A or B constrains ability to pursue the other for 3-4 rounds. Choosing Path C may permanently cede certain market segments if competitors establish positions.

---

### F. EMERGENT EVENTS AND SHOCKS

**Event Pool**

1. **Regulatory Enforcement Action**: A competitor receives enforcement action for practices similar to MedLink's. Likelihood increases if MedLink has pursued aggressive market expansion without proportionate compliance investment. Severity increases if MedLink has the same practices. Impact: Customer purchasing delays, increased compliance costs, potential for similar enforcement.

2. **Data Breach at Customer Site**: A MedLink customer experiences a data breach. Investigation reveals the breach occurred through systems adjacent to MedLink integration. Likelihood increases with number of customers and integration depth. Severity depends on MedLink's contractual liability and technical involvement. Impact: Reputation damage, potential litigation, sales cycle extension.

3. **Key Executive Departure**: A critical executive departs unexpectedly. Likelihood increases if compensation has not kept pace with market or if organizational conflict is unresolved. Impact varies by role: Sales VP departure damages pipeline, CTO departure damages product roadmap, GC departure damages regulatory relationships.

4. **Competitor Acquisition**: A major technology company acquires one of MedLink's direct competitors. Likelihood increases as market heats up. Impact: Competitive intensity increases, acquirer brings resources that smaller competitor lacked, MedLink's acquisition value may increase or decrease.

5. **Favorable Regulatory Development**: Regulatory body issues guidance that validates MedLink's technical approach and creates compliance pathway. Likelihood increases if MedLink has invested in regulatory relationships. Impact: Sales acceleration, competitive differentiation, reduced compliance uncertainty.

6. **Customer Bankruptcy**: A significant customer enters financial distress. Likelihood correlated with concentration in customer base. Impact: Revenue loss, accounts receivable write-off, reference customer no longer available.

7. **Technology Disruption**: Research publication or competitor announcement reveals technology that could obsolete MedLink's core approach. Likelihood increases in later rounds as market matures. Impact: R&D pivot required, product roadmap disrupted, investor confidence affected.

8. **Talent Market Shock**: Compensation expectations in the market shift significantly due to competitor funding or hyperscaler hiring. Likelihood increases in strong funding environments. Impact: Retention costs increase, hiring becomes more difficult, key personnel may depart.

9. **Partnership Opportunity**: A strategically important potential partner approaches MedLink about collaboration. Likelihood increases if MedLink has strong market position. Impact: Growth acceleration possible, but partnership terms require negotiation and may constrain independence.

10. **Activist Investor Interest**: A healthcare-focused activist investor begins accumulating position in MedLink's cap table (or signals interest in doing so post-IPO). Likelihood increases if company is underperforming relative to market opportunity. Impact: Board pressure increases, strategic options may be constrained or expanded depending on activist agenda.

11. **Macroeconomic Shock**: Interest rate changes, recession indicators, or healthcare spending policy shifts affect market conditions. Likelihood determined by external scenario parameters. Impact: Funding environment changes, customer budgets affected, growth assumptions disrupted.

12. **Cybersecurity Incident**: MedLink's own systems experience security incident. Likelihood increases with technical debt and decreases with security investment. Severity depends on data accessed and response speed. Impact: Reputation damage, regulatory scrutiny, customer churn risk.

13. **Whistleblower Complaint**: Current or former employee files complaint with regulatory body alleging compliance violations. Likelihood increases if employee satisfaction is low or if actual violations exist. Impact: Investigation triggered, management attention consumed, potential for public disclosure.

14. **Positive Press Coverage**: Major business publication profiles MedLink favorably. Likelihood increases with PR investment and newsworthy milestones. Impact: Brand awareness increases, inbound interest grows, employee recruiting benefits.

**Event Triggering Conditions**

Events are drawn from the pool based on probability weights that shift based on game state. Each round, the system evaluates:

- Base probability for each event type
- Modifiers based on player decisions (e.g., compliance investment reduces enforcement risk)
- Modifiers based on game history (e.g., rapid growth increases breach exposure)
- Modifiers based on round number (e.g., technology disruption more likely in later rounds)

Events can trigger conditionally on other events. Enforcement action against competitor increases probability of enforcement action against MedLink. Positive press coverage decreases probability of negative regulatory attention.

**Decision Influence on Event Severity**

When events trigger, severity is not fixed. Player decisions influence outcomes:

- Data breach severity reduced by security investment and incident response preparation
- Executive departure likelihood reduced by retention investment and conflict resolution
- Regulatory enforcement severity reduced by compliance posture and relationship investment
- Technology disruption impact reduced by R&D investment in next-generation capabilities

---

### G. END STATES AND COMPLETION LOGIC

**Game Termination Conditions**

The game ends after round 8 under normal conditions. Early termination occurs if:

- Cash reaches zero (bankruptcy)
- Board votes to remove CEO (governance failure)
- Regulatory action forces business cessation (compliance failure)
- Acquisition closes (strategic exit)

**Assessment Dimensions**

Performance is assessed across five dimensions, each scored 0-100:

**Financial Health (Weight: 25%)**
- Cash position relative to starting point and burn trajectory
- Revenue growth rate and quality (recurring vs. one-time)
- Path to profitability or sustainable funding
- Valuation trajectory implied by metrics

**Strategic Position (Weight: 25%)**
- Market share in target segments
- Competitive differentiation sustainability
- Platform and technology advantages
- Customer concentration and quality

**Organizational Resilience (Weight: 20%)**
- Executive team stability and capability
- Employee engagement and retention
- Operational efficiency and scalability
- Crisis response capability demonstrated

**Stakeholder Trust (Weight: 15%)**
- Customer satisfaction and Net Promoter Score
- Regulatory standing and relationships
- Investor confidence and support
- Public reputation and brand strength

**Long-Term Optionality (Weight: 15%)**
- Strategic flexibility for future pivots
- Technology platform extensibility
- Partnership and M&A attractiveness
- Talent pipeline and capability development

**Multiple Legitimate Success Paths**

The following endings qualify as successful outcomes:

1. **Category Leadership**: MedLink achieves dominant market position with sustainable competitive advantages. Financial metrics are strong, and the company is positioned for IPO or premium acquisition.

2. **Profitable Niche**: MedLink captures a defensible market segment with strong unit economics. Growth is moderate but sustainable. The company is profitable and self-funding.

3. **Strategic Acquisition**: MedLink is acquired by a larger player at a premium valuation. Shareholders achieve liquidity. Team members have favorable outcomes in combined entity.

4. **Platform Pivot**: MedLink's original market proves less attractive than anticipated, but technology assets enable pivot to adjacent opportunity. Company emerges stronger in different market than originally targeted.

**Non-Obvious Failure Modes**

1. **Zombie Company**: MedLink survives but fails to achieve escape velocity. Growth stalls, talent departs for better opportunities, investors lose interest. The company continues operating but has no path to meaningful outcome. This ending often results from conservative decision-making that avoids obvious failures but also avoids necessary risks.

2. **Pyrrhic Victory**: MedLink achieves market leadership but destroys value in the process. Aggressive tactics damage reputation, regulatory relationships, and organizational culture. The company "wins" but the victory is hollow. This ending often results from excessive focus on market share metrics without attention to organizational health.

---

### H. REPLAYABILITY LOGIC

**Why the Same Game Plays Differently Across Runs**

1. **Configuration Variation**: Four starting configurations create fundamentally different strategic contexts. First-Mover Advantage rewards speed; Regulatory Headwinds rewards caution; Partnership Dependent rewards relationship-building; International Expansion rewards geographic thinking.

2. **Role Assignment**: Different players in different roles produce different decision patterns. A risk-tolerant player in the Legal role makes different choices than a risk-averse player. Seven roles with different personality assignments create enormous combinatorial variation.

3. **Event Stochasticity**: The event pool contains more events than can occur in a single playthrough. Different event sequences create different challenges and opportunities. A game where competitor is acquired early plays very differently from one where key executive departs early.

4. **Path Dependency**: Decisions made in early rounds compound through the game. Identical teams starting with identical configurations will diverge based on round 1-2 decisions, and that divergence amplifies through rounds 3-8.

5. **Competitive Dynamics**: The simulation includes AI-controlled competitors whose behavior responds to MedLink's actions. Different MedLink strategies elicit different competitive responses, creating emergent dynamics.

**Facilitator-Tunable Parameters**

- Event pool composition (can add, remove, or re-weight events)
- Starting configuration selection
- Round timing (faster or slower play)
- Information revelation (more or less transparency between roles)
- Competitive intensity (more or less aggressive AI competitors)
- Regulatory environment (more or less enforcement risk)
- Funding environment (more or less available capital)

**Mastery Difficulty**

Players who have completed one playthrough understand basic mechanics but cannot "solve" the game because:

- Optimal strategy depends on configuration and events, which vary
- Role interdependencies require coordination that cannot be practiced solo
- Stochastic elements prevent deterministic planning
- Late-game events can disrupt seemingly optimal positions
- Competitor AI adapts to player patterns observed in early rounds

True mastery requires:
- Developing transferable frameworks for evaluating tradeoffs rather than memorized solutions
- Building capability to coordinate under uncertainty with incomplete information
- Learning to make decisions with appropriate confidence intervals rather than false precision
- Understanding second-order effects and long-term consequences of short-term choices

---

# GAME 2: MARGIN CALL
## Scale-up vs. Profitability Tradeoff in Competitive Markets

---

### A. CORE SCENARIO

**Industry Context**

Margin Call places participants inside a consumer fintech company operating in the embedded payments space. The company, PayStream, provides white-label payment processing infrastructure that enables non-financial companies to offer payment services to their customers. The market sits at the intersection of financial services, software platforms, and regulatory compliance.

The embedded finance market is expanding rapidly as traditional industry boundaries blur. Retailers want to offer financing. Software platforms want to capture transaction revenue. Employers want to provide financial wellness services. PayStream's technology enables all of these use cases through a unified API layer.

The market is crowded. Three well-funded competitors have raised more capital than PayStream. Two incumbent payment processors are building competitive offerings. The market is growing at 40% annually, but growth is fragmenting across verticals with different requirements.

**Company Maturity**

PayStream is a Series B company with $68 million in total funding. The company has 180 employees concentrated in engineering and operations. Revenue is $24 million ARR, growing 85% year-over-year. The company is not profitable and is not expected to reach profitability for 3+ years under current trajectory.

Gross margins are 62%, healthy for the industry but under pressure from pricing competition. Operating expenses are $42 million annually, producing a net loss of $18 million. Current runway is 22 months without additional revenue or cost reduction.

The board includes the founder-CEO, two venture partners from Series A and B rounds, and an independent director with payments industry experience. The Series B lead has communicated that Series C will require either a clear path to profitability or market-leading growth metrics. Current trajectory delivers neither.

**Competitive Landscape**

The competitive landscape includes three categories of threat:

Well-funded direct competitors (Marqeta, Stripe Treasury, Unit) have raised $500M+ and are pursuing market share without profitability constraints. They can sustain pricing pressure indefinitely. They have strong brand recognition and enterprise sales capabilities.

Incumbent payment processors (Fiserv, FIS, Global Payments) are building embedded finance offerings to protect existing relationships. They have distribution advantages through existing customer bases. Their technology is less elegant but their relationships are deep.

Vertical-specific specialists are emerging in healthcare payments, real estate, and logistics. They sacrifice breadth for depth and may capture the most valuable segments.

**Macro and Regulatory Environment**

Interest rate environment has shifted. Higher rates improve PayStream's economics (float income) but reduce customer willingness to invest in new initiatives. Venture funding has tightened. Series C rounds are smaller and require stronger metrics than 18 months ago.

Regulatory attention to fintech is increasing. Banking-as-a-service models face scrutiny. PayStream's bank partners are under examination. Any compliance issue at a bank partner could disrupt PayStream's operations.

Consumer protection regulation is expanding. CFPB is more active. State-level regulation is fragmenting. Compliance costs are rising across the industry.

**Initial Strategic Tension**

PayStream must decide whether to prioritize growth to capture market position before the window closes, or shift toward profitability to extend runway and reduce financing risk. The math does not easily reconcile.

Pursuing growth requires continued investment in sales, product, and customer success. Current burn rate is already high. Accelerating growth means accelerating burn, shortening runway, and increasing dependence on Series C that is not guaranteed.

Pursuing profitability requires cost reduction and pricing discipline. Cutting investment slows growth, potentially below competitive threshold. Raising prices may accelerate churn. Competitors not facing profitability pressure can undercut PayStream indefinitely.

The board is divided. The Series B lead prefers growth. The Series A investor prefers profitability. The independent director believes neither path is viable without strategic repositioning. The CEO must navigate these tensions while managing a leadership team with their own perspectives.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: Growth Trap**

Market structure shows first-mover advantages accruing to largest players. Customer acquisition costs are rising as competition intensifies. PayStream's growth rate is strong but decelerating while competitors accelerate.

Cost base is bloated from rapid scaling. Headcount grew faster than revenue. Sales productivity is below benchmark. Customer success is overwhelmed by support volume.

Talent profile is strong in engineering, weak in go-to-market. The VP of Sales was an early hire who grew into the role but lacks enterprise sales experience. Marketing is understaffed.

Financial runway is 22 months. Series C conversations have stalled. Investors want to see either path to profitability or acceleration to category leadership. Current trajectory delivers neither.

**Configuration 2: Margin Pressure**

Market structure is commoditizing. Pricing power is eroding. Customers are playing vendors against each other. Contract renewals are requiring discounts.

Cost base is optimized. The company has already implemented efficiency measures. Further cuts would affect product development or customer experience.

Talent profile is balanced but retention is challenging. Competitors are recruiting PayStream employees aggressively. Compensation is below market due to cash constraints.

Financial runway is 26 months due to previous cost optimization. However, growth has slowed and churn has increased. The company is optimizing toward a smaller outcome.

**Configuration 3: Vertical Concentration**

Market structure shows PayStream with dominant position in one vertical (retail) but minimal presence in others. Vertical concentration creates customer reference advantages but also concentration risk.

Cost base is efficient within the vertical but would require significant investment to expand to other verticals.

Talent profile is deep in retail domain expertise but lacks knowledge of other verticals. Expansion would require significant hiring.

Financial runway is 24 months. The company could reach profitability by doubling down on retail vertical, but total addressable market would be constrained.

**Configuration 4: International Opportunity**

Market structure shows PayStream with strong US position but competitors moving aggressively into Europe and Latin America. International expansion could provide growth runway but requires significant investment.

Cost base is US-centric. International expansion would require entity establishment, local compliance, and go-to-market investment.

Talent profile is US-focused. No executives have international fintech experience.

Financial runway is 22 months. International expansion would accelerate burn but potentially unlock new funding sources (European investors, strategic partners).

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

**STRATEGY ROLE**

Unique Private Information: Strategy sees board dynamics and investor sentiment that other roles do not. They know that the Series B lead is managing toward a specific fund return target and needs PayStream to either exit or reach $100M ARR within specific timeframe. They see competitive intelligence suggesting one competitor is running low on capital.

Decision Levers:
- Strategic positioning (horizontal platform vs. vertical specialist vs. geographic focus)
- Resource allocation frameworks for the company
- Investor communication and narrative management
- M&A posture (acquire, be acquired, partner)
- Pricing strategy philosophy (penetration vs. value capture)

Time-Delayed Consequences: Strategic repositioning takes 3-4 rounds to manifest in market perception. Investor narrative changes take 2 rounds to affect funding conversations.

Conflicts: Strategy conflicts with Sales over discounting that captures share but destroys unit economics. Strategy conflicts with Product over platform breadth vs. vertical depth.

Metrics: Internal - board confidence, strategic clarity. External - competitive position, valuation trajectory.

**MARKETING ROLE**

Unique Private Information: Marketing sees brand perception data and competitive positioning research. They know that PayStream's brand is perceived as "smaller" than actual capabilities. They have intelligence on competitor marketing spend.

Decision Levers:
- Brand positioning evolution
- Demand generation investment allocation
- Pricing communication and packaging
- Competitive response campaigns
- Customer evidence and proof point development

Time-Delayed Consequences: Brand investment requires 4-5 rounds to shift enterprise perception. Demand generation shows pipeline impact in 2 rounds, revenue in 4 rounds.

Conflicts: Marketing conflicts with Sales over lead quality. Marketing conflicts with Finance over spending that cannot demonstrate immediate ROI.

Metrics: Internal - pipeline contribution, brand awareness. External - share of voice, market positioning.

**PRODUCT / SUPPLY ROLE**

Unique Private Information: Product sees technical debt and platform architecture constraints. They know that a major customer integration is fragile and would require 3 months to stabilize if it fails. They see emerging platform requirements that customers have not yet articulated.

Decision Levers:
- Roadmap prioritization across verticals
- Platform investment vs. feature development
- Build vs. buy vs. partner decisions
- Technical debt management
- Release velocity and quality tradeoffs

Time-Delayed Consequences: Platform investments show returns in 4-5 rounds. Technical debt deferred compounds and constrains later options.

Conflicts: Product conflicts with Sales over customer-specific features vs. platform scalability. Product conflicts with R&D over research vs. development resource allocation.

Metrics: Internal - platform stability, roadmap execution. External - feature competitiveness, customer satisfaction.

**R&D ROLE**

Unique Private Information: R&D sees technology evolution in adjacent spaces. They know that a new payment rail is emerging that could disrupt current architecture in 24 months. They see patent exposure that could create licensing obligations.

Decision Levers:
- Research investment allocation
- Technology architecture decisions
- Patent strategy
- Academic and ecosystem partnerships
- Build vs. license technology decisions

Time-Delayed Consequences: Research investments show technology output in 4-5 rounds. Architecture decisions made early constrain or enable later pivots.

Conflicts: R&D conflicts with Product over research resource allocation. R&D conflicts with Finance over long-term investments without near-term payback.

Metrics: Internal - innovation pipeline, technical talent. External - technology differentiation, partner interest.

**SALES ROLE**

Unique Private Information: Sales sees customer buying signals and competitive pricing. They know that three major prospects are in parallel conversations with competitors. They know specific deal terms that competitors have offered.

Decision Levers:
- Territory and segment prioritization
- Pricing authority and discounting limits
- Sales team composition and compensation
- Channel partner development
- Customer success investment for retention

Time-Delayed Consequences: Pipeline built in round N converts in rounds N+2 to N+4. Pricing decisions establish expectations. Customer success investment prevents churn 3-4 rounds later.

Conflicts: Sales conflicts with Product over feature gaps. Sales conflicts with Finance over discounting authority.

Metrics: Internal - quota attainment, efficiency. External - market share, logo acquisition.

**LEGAL / REGULATORY ROLE**

Unique Private Information: Legal sees regulatory risk and bank partner dynamics. They know that PayStream's primary bank partner is under examination and may need to reduce fintech exposure. They see contract terms that create liability exposure.

Decision Levers:
- Compliance investment prioritization
- Bank partner relationship management
- Contract negotiation parameters
- Regulatory engagement strategy
- Risk management frameworks

Time-Delayed Consequences: Compliance investments pay off in 3-4 rounds during regulatory examinations. Bank partner relationships managed well provide stability; managed poorly create disruption.

Conflicts: Legal conflicts with Sales over contract terms. Legal conflicts with Product over compliance requirements in product development.

Metrics: Internal - compliance status, risk management. External - regulatory standing, partner confidence.

**GENERAL MANAGEMENT ROLE**

Unique Private Information: General Management sees organizational dynamics and cash flow projections. They know that two senior leaders are interviewing elsewhere. They see weekly cash position that creates constraints.

Decision Levers:
- Executive team performance management
- Organizational structure decisions
- Capital allocation across functions
- Culture and retention investments
- External stakeholder management

Time-Delayed Consequences: Organizational changes take 2-3 rounds to affect performance. Executive departures create 1-2 round capability gaps.

Conflicts: General Management must balance all functional demands against resource constraints.

Metrics: Internal - organizational health, efficiency. External - company performance, leadership reputation.

---

### D. ROUND STRUCTURE AND PACING

**Round Duration**: 8 rounds representing 2 years of company operations (quarterly cycles)

**Phase 1: Sensemaking (5 minutes)**
- Each role receives financial metrics, competitive intelligence, customer health data
- Hidden: other roles' private information, competitor strategic intent
- Noise: market sizing that varies by source, customer signals that may be leverage tactics

**Phase 2: Decision Submission (8 minutes)**
- Resource allocation across functions
- Strategic positioning choices
- Pricing and go-to-market decisions
- Risk posture selections

**Phase 3: System Resolution (5 minutes)**
- Revenue and margin outcomes
- Competitive dynamics resolution
- Cash position updates
- Event triggering

**Phase 4: Feedback and Narrative Update (7 minutes)**
- Updated dashboards
- Facilitator narrative
- Cross-functional visibility on company-level metrics

---

### E. DECISION TREES AND BRANCHING PATHS

**Strategic Fork 1: Pricing Response to Competitive Pressure (Round 2-3)**

Trigger: Major competitor announces 25% price reduction across all products.

Path A - Match Pricing: Reduce prices to maintain competitive position. Requires accepting margin compression or cost reduction.

Consequences:
- Revenue per customer declines 20-25%
- Churn prevention (retention improves)
- Profitability timeline extends significantly
- Cost reduction required to maintain runway
- May trigger further competitive price cuts

Path B - Hold Pricing, Add Value: Maintain pricing but invest in product differentiation and customer success.

Consequences:
- Some churn to price-sensitive customers
- Margin preservation for remaining customers
- Product and success investment required
- Differentiation may or may not be valued by market
- Risk of being perceived as premium when market commoditizes

Path C - Segment Pricing: Differentiated pricing by customer segment or use case.

Consequences:
- Complexity in sales and operations
- Can compete on price in price-sensitive segments
- Can preserve margin in value-seeking segments
- Risk of arbitrage between segments
- Requires segmentation capability that may not exist

**Strategic Fork 2: Vertical Expansion vs. Deepening (Round 4-5)**

Trigger: PayStream has established position in retail vertical. Healthcare and logistics verticals show opportunity but require investment.

Path A - Vertical Expansion: Invest in entering healthcare vertical.

Consequences:
- R&D investment required for healthcare-specific compliance
- Sales investment required for healthcare relationships
- 12-18 month timeline to meaningful healthcare revenue
- Retail investment slows, creating opening for competitors
- If healthcare succeeds, TAM expands significantly
- If healthcare fails, capital consumed without return

Path B - Vertical Deepening: Double down on retail, capture dominant position.

Consequences:
- Efficiency gains from focus
- Market share gains in retail
- TAM constrained to retail payments
- Competitors may capture other verticals that become strategic
- Path to profitability clearer
- Platform may become less valuable for horizontal plays

Path C - Platform Play: Invest in horizontal capabilities that enable any vertical.

Consequences:
- Highest investment requirement
- Longest time to payoff
- Greatest eventual TAM if successful
- Risk of being outcompeted by vertical specialists in each vertical
- Requires Series C to fund execution
- Most attractive strategically, most risky financially

**Strategic Fork 3: Acquisition Opportunity (Round 6-7)**

Trigger: A smaller competitor approaches about acquisition by PayStream, or a larger player approaches about acquiring PayStream.

Path A - Acquire Competitor: Use equity and limited cash to acquire smaller competitor.

Consequences:
- Market share increases immediately
- Technology and talent acquired
- Integration risk and management distraction
- Cash drain from integration costs
- Competitor removed from market
- Valuation impact depends on execution

Path B - Be Acquired: Engage in acquisition discussions with larger player.

Consequences:
- Potential premium exit for shareholders
- Loss of independence
- Management uncertainty
- If deal fails, company damaged by distraction and information leakage
- If deal succeeds, simulation ends

Path C - Decline Both: Maintain independence and organic strategy.

Consequences:
- Strategic flexibility preserved
- Opportunity cost if competitor acquisition would have been valuable
- If acquisition interest was real, may not return
- Standalone execution risk continues

---

### F. EMERGENT EVENTS AND SHOCKS

**Event Pool**

1. **Bank Partner Disruption**: Primary bank partner reduces fintech exposure or exits market
2. **Competitor Funding**: Competitor raises large round or is acquired
3. **Regulatory Action**: CFPB or state regulator takes action affecting business model
4. **Customer Bankruptcy**: Large customer enters distress
5. **Key Departure**: Critical executive or engineer departs
6. **Technology Failure**: Platform experiences significant outage
7. **Pricing War**: Competitor initiates aggressive pricing
8. **Market Downturn**: Macro conditions reduce customer spending
9. **Partnership Opportunity**: Strategic partner approaches
10. **Fraud Incident**: Customer or internal fraud detected
11. **Talent Market Shift**: Compensation expectations increase
12. **Positive Coverage**: Favorable analyst or press coverage
13. **Customer Concentration Event**: Largest customer renegotiates aggressively
14. **New Entrant**: Major technology company enters market

---

### G. END STATES AND COMPLETION LOGIC

**Successful Outcomes**
1. **Growth Leader**: PayStream achieves market leadership position with clear path to eventual profitability
2. **Profitable Niche**: PayStream achieves profitability in focused segment with sustainable competitive position
3. **Strategic Exit**: PayStream acquired at premium valuation with good outcomes for stakeholders
4. **Platform Evolution**: PayStream pivots to adjacent opportunity with stronger economics

**Non-Obvious Failure Modes**
1. **Growth Trap**: Growth continues but unit economics never improve; company needs perpetual funding
2. **Margin Death Spiral**: Cost cutting damages growth; smaller company with same percentage losses

---

### H. REPLAYABILITY LOGIC

Different configurations create different optimal strategies. Growth Trap requires efficiency focus; Margin Pressure requires growth acceleration. Role assignments change decision patterns. Event stochasticity creates unique challenges each playthrough. Competitive AI adapts to player patterns.

---

# GAME 3: PORTFOLIO ROULETTE
## Innovation Portfolio Management Under Resource Constraints

---

### A. CORE SCENARIO

**Industry Context**

Portfolio Roulette places participants inside the R&D division of a diversified industrial technology company. The company, Prometheus Technologies, develops advanced materials, precision manufacturing systems, and industrial automation solutions. The R&D portfolio spans fundamental research to near-term product development.

The industrial technology sector is experiencing disruption from multiple directions. Additive manufacturing threatens traditional machining. AI-enabled automation reduces labor requirements. Sustainability requirements force material science innovation. Supply chain reshoring creates both opportunity and complexity.

Prometheus has historically been a fast follower, allowing competitors to prove markets before entering with superior execution. This strategy is increasingly untenable as innovation cycles accelerate.

**Company Maturity**

Prometheus Technologies is a publicly traded company with $4.2 billion in revenue. R&D spending is $380 million annually, representing 9% of revenuebelow industry benchmarks of 11-13%. The R&D organization includes 2,400 employees across 8 global locations.

The R&D portfolio currently includes 47 active projects spanning three horizons: Horizon 1 (product extensions, 60% of budget), Horizon 2 (adjacent opportunities, 30%), and Horizon 3 (transformational bets, 10%). Horizon 3 projects have historically been underfunded and frequently cancelled.

The CEO has mandated R&D transformation. The board believes organic innovation has underperformed and is considering acquisitions. The CFO views R&D as a cost center to be optimized. The CTO believes budget constraints are the problem and advocates for increased investment.

**Competitive Landscape**

Competitors include both traditional industrial players and emerging technology companies:

Established competitors (Siemens, Honeywell, Emerson) have larger R&D budgets and global scale. They are pursuing similar technologies with more resources. Their innovation portfolios are more balanced across horizons.

Emerging competitors (startups in additive manufacturing, robotics, materials science) are focused and fast. They have raised significant venture capital. They threaten to leapfrog Prometheus in specific technology areas.

**Macro and Regulatory Environment**

Government R&D incentives are increasing through industrial policy initiatives. Tax credits for domestic manufacturing create opportunity. Defense and aerospace programs seek advanced materials suppliers.

Sustainability regulations require Prometheus products to meet new environmental standards within 5 years. Current portfolio may not deliver compliant products in time.

**Initial Strategic Tension**

The R&D leadership must allocate insufficient resources across too many opportunities while managing organizational politics that favor incremental projects over transformational bets. Every project has an internal sponsor. Every cancellation creates enemies.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: Portfolio Bloat**
47 active projects with insufficient resources. Projects compete for engineers, equipment, and management attention. Nothing moves fast enough. Cancellation politics paralyze decision-making.

**Configuration 2: Bet-the-Company Technology**
One Horizon 3 project has shown breakthrough results but requires 3x current investment to reach commercialization. Success would transform the company. Failure would waste 40% of annual R&D budget.

**Configuration 3: Acquisition Integration**
Prometheus recently acquired a startup with promising technology. Integration is consuming R&D leadership attention. Acquired team members are departing. Technology value is at risk.

**Configuration 4: Talent Crisis**
Key technical talent is departing for competitors and startups. Knowledge loss threatens project continuity. Compensation constraints prevent matching external offers.

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

[Detailed for all 7 roles: Strategy, Marketing, Product/Supply, R&D, Sales, Legal/Regulatory, General Management - each with unique private information, decision levers, time-delayed consequences, conflicts, and metrics as in Games 1 and 2]

**STRATEGY ROLE**

Unique Private Information: Strategy sees board deliberations on R&D effectiveness and acquisition alternatives. They know the CEO is evaluating whether to replace the CTO. They see competitive intelligence on rival R&D programs.

Decision Levers: Portfolio allocation frameworks, horizon balance targets, make-vs-buy decisions, strategic partnerships, technology licensing

Time-Delayed Consequences: Portfolio rebalancing takes 3-4 rounds to show results. Horizon 3 investments may not produce outcomes within simulation timeframe.

Conflicts: Strategy conflicts with R&D over project cancellations. Strategy conflicts with Finance over investment levels.

**R&D ROLE** (Central to this simulation)

Unique Private Information: R&D sees technical progress and obstacles that other roles do not. They know which projects are genuinely promising vs. politically protected. They see talent dynamics within technical teams.

Decision Levers: Project staffing, technical approach selection, milestone definitions, collaboration structures, talent development

Time-Delayed Consequences: Technical decisions made early constrain later options. Talent investments show retention impact in 2-3 rounds.

Conflicts: R&D conflicts with Strategy over project cancellations. R&D conflicts with Product over development timelines.

[Continue for Marketing, Product, Sales, Legal, General Management...]

---

### D. ROUND STRUCTURE AND PACING

10 rounds representing 2.5 years. Longer timeframe reflects R&D cycle times.

**Phase Structure**
- Sensemaking: Project status updates, competitive intelligence, resource constraints
- Decision Submission: Portfolio allocation, project decisions, talent investments
- System Resolution: Technical progress, milestone achievement, competitive developments
- Feedback: Updated project status, portfolio health metrics

---

### E. DECISION TREES AND BRANCHING PATHS

**Strategic Fork 1: Horizon 3 Investment Decision (Round 2-3)**

Trigger: Breakthrough Horizon 3 project requires decision on major investment.

Path A - Full Investment: Commit resources to accelerate breakthrough
Path B - Staged Investment: Incremental funding with milestone gates
Path C - Partnership: Seek external partner to share investment and risk
Path D - Divestiture: Spin out technology into separate entity

**Strategic Fork 2: Talent Crisis Response (Round 4-5)**

Trigger: Key technical talent departures threaten project continuity

Path A - Compensation Match: Increase compensation to retain talent
Path B - Project Consolidation: Reduce projects to match available talent
Path C - Acqui-hire: Acquire company to obtain talent
Path D - Outsourcing: Partner with universities or contractors

**Strategic Fork 3: Technology Direction (Round 6-7)**

Trigger: Competing technical approaches within portfolio require choosing direction

Path A - Internal Technology: Commit to internally developed approach
Path B - Licensed Technology: License external technology to accelerate
Path C - Hybrid: Pursue both approaches with increased investment
Path D - Wait and See: Delay decision pending additional information

---

### F. EMERGENT EVENTS AND SHOCKS

1. Competitor breakthrough announcement
2. Key patent invalidation
3. Star researcher departure
4. Government grant award
5. Regulatory requirement change
6. Customer technology mandate
7. Supply chain disruption affecting R&D materials
8. Acquisition offer for R&D division
9. Laboratory accident
10. University partnership opportunity
11. Technology standard adoption
12. Talent market shift
13. Budget cut mandate
14. Breakthrough discovery
15. Project failure

---

### G. END STATES AND COMPLETION LOGIC

**Successful Outcomes**
1. Innovation Engine: Portfolio produces breakthrough technology with commercial value
2. Efficient Incrementalist: Focused portfolio delivers reliable product improvements
3. Strategic Exit: R&D assets acquired at premium
4. Platform Pivot: Portfolio repositioned for emerging opportunity

**Non-Obvious Failure Modes**
1. Innovation Theater: High activity, no outcomes
2. Analysis Paralysis: Decision avoidance leads to drift

---

### H. REPLAYABILITY LOGIC

Configuration variation creates different portfolio challenges. Role assignments affect which projects receive advocacy. Event stochasticity changes technical outcomes. Breakthrough discoveries are probabilistic based on investment but not guaranteed.

---

# GAME 4: CRUCIBLE
## Crisis Leadership and Organisational Resilience

---

### A. CORE SCENARIO

**Industry Context**

Crucible places participants inside a global pharmaceutical company facing a cascading crisis. The company, Meridian Pharmaceuticals, discovers a potential safety signal in its best-selling drug during routine post-market surveillance. The drug generates $2.8 billion in annual revenue34% of company total.

The pharmaceutical industry operates under intense regulatory scrutiny. Safety signals require immediate reporting to FDA and EMA. Public disclosure requirements create communication challenges. Plaintiff attorneys monitor adverse event databases.

**Company Maturity**

Meridian Pharmaceuticals is a mature public company with $8.2 billion in revenue and 23,000 employees. The company has strong cash reserves ($4.1 billion) but limited pipeline to replace revenue loss. The drug in question, Cardiozen, treats a chronic condition in 4.2 million patients worldwide.

**Crisis Dynamics**

The safety signal involves potential increased cardiovascular events in patients over 65 with certain comorbidities. Initial data is ambiguoussignal may be real, may be statistical noise, or may reflect patient population characteristics rather than drug effect.

Time pressure is extreme. Every day of delay in reporting increases regulatory and legal risk. Every day of premature action destroys value if signal proves unfounded.

**Initial Strategic Tension**

Leadership must navigate between patient safety imperatives, regulatory requirements, shareholder interests, and employee welfare. No decision satisfies all stakeholders.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: Ambiguous Signal**
Safety data is genuinely ambiguous. Expert opinions differ. The right answer is not knowable with current information.

**Configuration 2: Clear Danger**
Additional analysis reveals signal is likely real. Scope and severity remain uncertain. Recall may be appropriate.

**Configuration 3: Manufacturing Quality Issue**
Investigation reveals potential manufacturing quality variation that may explain safety signal. Specific lots may be affected.

**Configuration 4: Competitor Disinformation**
Evidence emerges suggesting competitor may be amplifying safety concerns through planted stories and manipulated data.

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

**GENERAL MANAGEMENT ROLE** (Central to this simulation)

Unique Private Information: General Management sees board dynamics, regulatory relationships, and litigation exposure estimates.

Decision Levers: Crisis team composition, communication strategy, resource mobilization, regulatory engagement posture

Time-Delayed Consequences: Early communication choices constrain later options. Stakeholder trust lost is difficult to rebuild.

Conflicts: Must balance all stakeholder interests under extreme time pressure.

**LEGAL / REGULATORY ROLE** (Critical in this simulation)

Unique Private Information: Legal sees litigation exposure, regulatory precedents, and enforcement history.

Decision Levers: Disclosure timing, regulatory engagement strategy, litigation preparation, investigation scope

Time-Delayed Consequences: Disclosure decisions create permanent record. Regulatory relationships affect future product approvals.

Conflicts: Legal conflicts with Marketing over public communication. Legal conflicts with R&D over investigation scope.

[Continue for other roles with crisis-specific mechanics...]

---

### D. ROUND STRUCTURE AND PACING

6 rounds representing 6 weeks of crisis response. Compressed timeframe reflects crisis intensity.

**Phase Structure**
- Sensemaking: New data, media coverage, stakeholder reactions, regulatory communications
- Decision Submission: Investigation actions, communication decisions, resource deployment
- System Resolution: Crisis evolution, stakeholder response, regulatory actions
- Feedback: Crisis status, stakeholder trust metrics, financial impact

---

### E. DECISION TREES AND BRANCHING PATHS

**Strategic Fork 1: Initial Disclosure (Round 1-2)**

Trigger: Safety signal identified, disclosure decision required

Path A - Immediate Full Disclosure: Release all known information publicly
Path B - Regulatory-First Disclosure: Inform regulators, delay public announcement
Path C - Investigate First: Delay disclosure pending additional analysis
Path D - Voluntary Recall: Preemptive product withdrawal pending investigation

**Strategic Fork 2: Investigation Scope (Round 2-3)**

Trigger: Initial investigation requires scope decisions

Path A - Internal Investigation: Conduct investigation with internal resources
Path B - Independent Investigation: Engage external experts for credibility
Path C - Regulatory-Led Investigation: Invite regulatory participation
Path D - Joint Investigation: Collaborate with academic medical centers

**Strategic Fork 3: Stakeholder Communication (Round 4-5)**

Trigger: Investigation produces preliminary findings requiring communication

Path A - Transparent Communication: Share all findings including uncertainties
Path B - Confident Communication: Share conclusions with limited uncertainty discussion
Path C - Defensive Communication: Emphasize limitations of data and alternative explanations
Path D - Silence: Limit communication pending final conclusions

---

### F. EMERGENT EVENTS AND SHOCKS

1. Adverse event report (confirmed patient harm)
2. Whistleblower emergence
3. Media investigation
4. Congressional inquiry
5. Competitor statement
6. Patient advocacy response
7. Physician prescribing change
8. Insurance coverage decision
9. Stock analyst downgrade
10. Employee leak
11. Manufacturing discovery
12. Regulatory inspection
13. Plaintiff lawsuit filing
14. Expert opinion publication
15. International regulatory action

---

### G. END STATES AND COMPLETION LOGIC

**Successful Outcomes**
1. Trusted Leader: Company emerges with enhanced reputation for patient safety commitment
2. Contained Crisis: Damage limited, operations continue, trust preserved
3. Controlled Exit: Product withdrawn but company franchise protected
4. Vindication: Signal proves unfounded, company reputation intact

**Non-Obvious Failure Modes**
1. Cover-up Perception: Legitimate actions perceived as concealment
2. Overcorrection: Excessive response destroys value unnecessarily

---

### H. REPLAYABILITY LOGIC

Configuration determines whether crisis is real or perceived. Role assignments affect organizational response capability. Event stochasticity creates unique crisis trajectories. Same decisions can produce different outcomes depending on underlying reality.

---

# GAME 5: ENTANGLED
## Ecosystem Strategy and Partner Dependence

---

### A. CORE SCENARIO

**Industry Context**

Entangled places participants inside a software company heavily dependent on platform ecosystem relationships. The company, CloudBridge, provides integration middleware that connects enterprise applications running on major cloud platforms. The business model depends on marketplace presence, API access, and co-selling relationships with platform providers.

The cloud platform ecosystem is dominated by three hyperscalers (AWS, Azure, GCP). Each platform has its own marketplace, partner program, and strategic priorities. Platform relationships can make or break companies like CloudBridge.

**Company Maturity**

CloudBridge has $156 million ARR and 680 employees. The company is profitable but growth has slowed as platform providers have introduced competing native capabilities. 73% of revenue comes through platform marketplaces, creating concentration risk.

**Ecosystem Dynamics**

Platform providers are simultaneously partners and potential competitors. They provide distribution and credibility but can also copy successful partner capabilities. The relationship requires constant navigation.

**Initial Strategic Tension**

CloudBridge must decide whether to deepen platform dependencies to accelerate growth, diversify across platforms to reduce risk, or build direct customer relationships independent of platforms. Each path has different risk/reward profiles.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: Platform Favorite**
CloudBridge has strong relationship with one platform provider who is investing in co-marketing. Deepening this relationship could accelerate growth but increases dependency.

**Configuration 2: Platform Threat**
The largest platform partner has announced native capabilities that overlap with CloudBridge's core product. Competitive dynamics are shifting.

**Configuration 3: Multi-Platform Complexity**
CloudBridge operates across all three platforms but lacks deep relationship with any. Breadth creates complexity without partnership benefits.

**Configuration 4: Direct Channel Opportunity**
Enterprise customers are expressing interest in direct relationships independent of platforms. Building direct channel would reduce dependency but requires significant investment.

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

[Detailed for all 7 roles with ecosystem-specific mechanics]

**STRATEGY ROLE**

Unique Private Information: Strategy sees platform partner roadmaps that suggest future competitive moves. They know which platform is considering acquisition of companies like CloudBridge.

Decision Levers: Platform prioritization, partnership depth vs. breadth, direct channel investment, acquisition targets

**SALES ROLE**

Unique Private Information: Sales sees platform partner deal dynamicswhich opportunities platforms support vs. ignore vs. undermine.

Decision Levers: Channel mix decisions, platform relationship management at account level, direct sales investment

---

### D-H. [Structure mirrors previous games]

**Strategic Forks**
1. Platform Exclusivity Decision
2. Direct Channel Investment
3. Acquisition or Acqui-hire Target
4. Response to Platform Competition

**Event Pool**
Platform policy changes, API deprecation, marketplace algorithm changes, partner program restructuring, platform acquisition activity, competitive partnership announcements, customer platform migration, regulatory action affecting platforms

---

# GAME 6: METAMORPHOSIS
## Long-term Transformation and Cultural Change

---

### A. CORE SCENARIO

**Industry Context**

Metamorphosis places participants inside a traditional industrial company attempting fundamental business model transformation. The company, Sterling Manufacturing, is a 90-year-old producer of precision mechanical components facing digital disruption.

The manufacturing industry is experiencing Industry 4.0 transformation. Digital twins, predictive maintenance, and IoT-enabled products are becoming standard. Traditional manufacturers must transform or face obsolescence.

**Company Maturity**

Sterling Manufacturing has $1.9 billion in revenue and 8,400 employees across 12 facilities. The company is profitable but margins are declining and growth has stalled. The workforce averages 52 years old with 18 years average tenure. Technical skills are concentrated in mechanical engineering; digital capabilities are minimal.

**Transformation Dynamics**

The CEO has committed to transformation but faces an organization resistant to change. Middle management is entrenched. Union relationships are complicated. Customer expectations are evolving faster than Sterling can adapt.

**Initial Strategic Tension**

Leadership must transform the company's capabilities, culture, and business model while maintaining operational performance and employee stability. Moving too fast creates resistance; moving too slow allows competitors to establish insurmountable leads.

---

### B. INTERNAL CONFIGURATIONS

**Configuration 1: Burning Platform**
Largest customer has issued ultimatum: provide digital capabilities within 18 months or lose the contract (28% of revenue).

**Configuration 2: Gradual Decline**
No immediate crisis but metrics are declining steadily. Transformation is strategic imperative but urgency is difficult to communicate.

**Configuration 3: Acquisition Integration**
Sterling has acquired a digital technology company. Integration is failing. Acquired employees are departing. Cultural clash is severe.

**Configuration 4: Labor Relations Complexity**
Union negotiations are ongoing. Transformation plans affect work rules and job classifications. Strike risk complicates transformation timing.

---

### C. ROLE-SPECIFIC GAMEPLAY DEPTH

**GENERAL MANAGEMENT ROLE** (Central to this simulation)

Unique Private Information: General Management sees organizational dynamics, change readiness assessments, and informal power structures.

Decision Levers: Transformation program design, change management approach, communication strategy, leadership development

**HR / ORGANIZATIONAL ROLE** (Added for this simulation)

Unique Private Information: HR sees employee sentiment data, turnover risk assessments, and skills gap analysis.

Decision Levers: Training program design, hiring strategy, compensation structure, performance management evolution

---

### D-H. [Structure mirrors previous games with transformation-specific mechanics]

**Strategic Forks**
1. Transformation Pace (Radical vs. Incremental)
2. Talent Strategy (Reskill vs. Replace)
3. Cultural Approach (Top-Down vs. Grassroots)
4. Legacy Business Management (Protect vs. Harvest)

**Event Pool**
Key transformation leader departure, union action, customer loss, transformation success story, cultural resistance incident, skills shortage, competitor transformation announcement, technology implementation failure, change fatigue, grassroots innovation emergence

**Time Horizon**
10 rounds representing 2.5 years. Transformation timeline reflects cultural change dynamics.

---

## DOCUMENT CONCLUSION

This specification defines six fundamentally different simulation experiences:

1. **Nexus Protocol**: Regulatory strategy under platform dynamics
2. **Margin Call**: Growth vs. profitability tradeoffs in competitive markets
3. **Portfolio Roulette**: Innovation portfolio management with resource constraints
4. **Crucible**: Crisis leadership and organizational resilience
5. **Entangled**: Ecosystem strategy and partner dependence
6. **Metamorphosis**: Long-term transformation and cultural change

Each game operates as a complete system with distinct mechanics, role dynamics, and strategic challenges. The games cannot be "solved" through single playthroughs due to configuration variation, role assignment effects, event stochasticity, and adaptive competitive dynamics.

The specifications are designed for:
- Product design input for simulation engine development
- Academic validation material for business school partnerships
- Facilitator training documentation
- Player briefing foundations

---

*End of Specification Document*
